Skip Navigation Archive: U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality
Archive print banner

Fewer than Half of Schizophrenia Patients Get Proper Treatment

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Press Release Date: March 24, 1998

Fewer than half of the patients under treatment for schizophrenia, a serious brain disorder, are receiving proper doses of antipsychotic medications or appropriate psychosocial interventions. This finding is from a national study on schizophrenia, funded by the Agency for Health Care Policy and Research (AHCPR) and the National Institute of Mental Health (NIMH), and published recently in NIMH's Schizophrenia Bulletin. The study identified gaps in effective care for people with schizophrenia and opportunities for improvement in all aspects of treatment.

"Appropriate medication is the cornerstone to treating the illness, but medication alone is not enough," said Anthony F. Lehman, M.D., Principal Investigator of the study and Director of the Center for Mental Health Services Research at the University of Maryland School of Medicine. "Clinicians understand the need to prescribe antipsychotic medications, but the most effective approach integrates appropriate medication management with psychosocial treatments."

Schizophrenia may be the most disabling of all mental illnesses. The symptoms, which can be devastating to the individual and his or her family and friends, impair a person's ability to make decisions, manage emotions, interact with others, and think clearly. The symptoms commonly include hallucinations, delusions, confused thinking, and blunted or altered emotions or senses. It is not a multiple-personality disorder, as is often thought. Typically, schizophrenia has an early onset (usually between the ages of 16 and 30). Up to 2 million people are treated for the illness each year, and up to 100,000 patients with schizophrenia are in public mental health hospitals on any given day.

The study's new evidence-based analysis is intended to inform health professionals of more effective medical approaches to treat patients suffering from schizophrenia. The five-year scientific study found that the key to improving outcomes for patients is adoption of a comprehensive and individualized strategy—combining proper doses of appropriate medications, patient and family education and support, and, for high risk patients, assertive community treatment.

The researchers analyzed published research on schizophrenia and assessed the quality of evidence for schizophrenia treatment. Then, to better understand how to improve care, they studied how this evidence compares with current clinical practice. Their study evaluated care of schizophrenic patients in outpatient and inpatient settings in both urban and rural settings. The overall rates at which patients' treatments conformed to the study recommendations were generally below 50 percent. An exception was the rate of prescription for antipsychotic medications, which was found to be around 90 percent, although not always at an appropriate dosage.

"This study is an excellent example of how research can identify opportunities for improvement in health care quality," said AHCPR Administrator John M. Eisenberg, M.D. "The study gives clinicians, patients and their families the basic, evidence-based information they need to form a comprehensive treatment plan for people with schizophrenia."

"This is an extremely exciting time in schizophrenia research, with the recent introduction of several new and safer antipsychotic medications, said Steven E. Hyman, M.D., Director, National Institute of Mental Health. "The study's results demonstrate the importance of getting information about the best available treatments to clinicians, large and small provider groups, and patients and their families."

Other findings include:

  • Younger patients were more likely to be offered psychotherapy and vocational rehabilitation. Minority patients were more likely to be on higher doses of antipsychotic medications and less often prescribed an antidepressant when depressed.
  • Psychosocial treatments are often prescribed at the point of hospital discharge but follow-through in the community is low. Failure to offer these treatments for outpatients may be a serious problem in ongoing community-based care.
  • Psychosocial treatment varied in conformance rates based on location. Patients in some states are more likely than those of another to be prescribed a vocational intervention and less likely to be prescribed a family intervention or psychotherapy.

This study was part of AHCPR's Patient Outcomes Research Team (PORT) program, which examines the effectiveness and cost effectiveness of available treatments for common clinical conditions. PORT projects focus on procedures and treatments whose use in the "real world" setting of medical practice has not been rigorously evaluated.

The complete PORT findings are published in the Schizophrenia Bulletin, available from the National Institute of Mental Health (301-443-4536). Reprints of the journal articles (packaged as AHCPR Pub. 98-R036 and 98-R037) are available from the AHCPR Publications Clearinghouse. Call 1-800-358-9295 or write to P.O. Box 8547, Silver Spring, MD 20907. Other information about schizophrenia is available from the NIMH and from the National Alliance for the Mentally Ill (703-524-7600).

For additional information contact AHCPR Public Affairs: Karen Carp, (301) 427-1858 (; Salina Prasad, (301) 427-1864. Or contact NIMH Public Affairs at (301) 443-4536. For an interview with the study's Principal Investigator, Tony Lehman, M.D., please contact Ellen Beth Levitt at the University of Maryland Medical Center Press Office, (410) 328-8919.

For an interview with the co-Principal Investigator, Donald Steinwachs, Ph.D., please contact Sharon Rippey at Johns Hopkins School of Public Health, Office of Public Affairs, (410) 955-6878.

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care